Trial Profile
Efficacy of Sunitinib as first line treatment in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SANTORIN
- 12 Jan 2018 New trial record